Miranda Adrian reported grant involving 337,204 derivative units of Neuraxis, INC on Aug 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CMO, SVP Science & Tech
CMO, SVP Science & Tech
Filed Aug 26, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
337,204RSU
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
337,204Direct
Trade date
Aug 24, 2026Grant
Filed
Aug 26, 2026, 5:30 PM ET2-day reporting delay
Accession
0001493152-26-040276Code A · Transaction 103146
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 24, 2026Conversion337,204$6.94−$2,340,195.76Trade 103145
Aug 24, 2026Conversion337,204——Trade 103147
Aug 24, 2026Grant199,106——Trade 103144
4 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

NRXS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NRXS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago +5.4%1d ago +3.2%
Returns since7d −0.2%30d +27%90d180d1y

Footnotes in full

F1: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.